SLC45A3

Summary

SLC45A3 (solute carrier family 45 member 3, HGNC:8642) is a protein-coding gene on chromosome 1q32.1, encoding Solute carrier family 45 member 3 (Q96JT2). Proton-associated sucrose transporter.

Predicted to enable sucrose:proton symporter activity. Predicted to be involved in positive regulation of small molecule metabolic process; regulation of oligodendrocyte differentiation; and sucrose transport. Predicted to be located in plasma membrane. Predicted to be active in membrane.

Source: NCBI Gene 85414 — RefSeq curated summary.

At a glance

• GWAS associations: 20
• Clinical variants (ClinVar): 74 total
• Druggable target: yes
• MANE Select transcript: NM_033102

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8642
Approved symbol	SLC45A3
Name	solute carrier family 45 member 3
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	IPCA-6, prostein, IPCA-2, IPCA-8
Ensembl gene	ENSG00000158715
Ensembl biotype	protein_coding
OMIM	605097
Entrez	85414

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 17 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000367145, ENST00000460934, ENST00000891085, ENST00000891086, ENST00000891087, ENST00000891088, ENST00000891089, ENST00000891090, ENST00000891091, ENST00000891092, ENST00000891093, ENST00000891094, ENST00000891095, ENST00000891096, ENST00000934615, ENST00000934616, ENST00000942928, ENST00000942929

RefSeq mRNA: 1 — MANE Select: NM_033102 NM_033102

CCDS: CCDS1458

Canonical transcript exons

ENST00000367145 — 5 exons

Exon	Start	End
ENSE00001040528	205662833	205663618
ENSE00001443627	205664485	205664886
ENSE00001443628	205680394	205680509
ENSE00003644968	205661861	205662126
ENSE00003694656	205657851	205659671

Expression profiles

Bgee: expression breadth ubiquitous, 203 present calls, max score 93.83.

FANTOM5 (CAGE): breadth broad, TPM avg 1.8096 / max 96.2539, expressed in 859 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
17013	1.0848	642
17012	0.3018	82
17011	0.2361	93
17010	0.1466	65
17014	0.0403	21

Top tissues by expression

243 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
prostate gland	UBERON:0002367	93.83	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	92.94	gold quality
oocyte	CL:0000023	91.63	gold quality
spinal cord	UBERON:0002240	91.61	gold quality
pancreatic ductal cell	CL:0002079	89.04	silver quality
nasal cavity epithelium	UBERON:0005384	87.91	gold quality
secondary oocyte	CL:0000655	87.09	gold quality
ileal mucosa	UBERON:0000331	86.71	gold quality
right lobe of liver	UBERON:0001114	86.60	gold quality
spleen	UBERON:0002106	86.50	gold quality
kidney epithelium	UBERON:0004819	85.88	gold quality
inferior vagus X ganglion	UBERON:0005363	85.64	gold quality
epithelial cell of pancreas	CL:0000083	84.83	gold quality
mucosa of transverse colon	UBERON:0004991	84.08	gold quality
substantia nigra	UBERON:0002038	83.70	gold quality
midbrain	UBERON:0001891	82.55	gold quality
corpus callosum	UBERON:0002336	82.39	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.61	gold quality
liver	UBERON:0002107	80.17	gold quality
subthalamic nucleus	UBERON:0001906	80.08	gold quality
rectum	UBERON:0001052	79.35	gold quality
body of stomach	UBERON:0001161	79.30	gold quality
Ammon’s horn	UBERON:0001954	79.12	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.04	gold quality
Brodmann (1909) area 46	UBERON:0006483	78.24	gold quality
right coronary artery	UBERON:0001625	77.73	gold quality
stomach	UBERON:0000945	77.29	gold quality
transverse colon	UBERON:0001157	77.29	gold quality
right adrenal gland	UBERON:0001233	77.25	gold quality
ascending aorta	UBERON:0001496	77.19	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-MTAB-9067	yes	19.46
E-CURD-112	yes	14.40
E-CURD-122	yes	8.88
E-MTAB-9801	yes	8.45
E-MTAB-8410	yes	8.28
E-ANND-3	yes	6.13
E-GEOD-99795	no	90.67
E-MTAB-6678	no	3.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

93 targeting SLC45A3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-221-3P	99.86	71.56	1329
HSA-MIR-222-3P	99.86	71.35	1337
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-636	99.80	69.58	1500
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-1825	99.72	68.11	1089
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-6752-5P	99.59	67.32	1243
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-671-5P	99.52	67.11	1277
HSA-MIR-5007-3P	99.51	68.14	1242
HSA-MIR-3128	99.50	67.85	1258

Literature-anchored findings (GeneRIF, showing 18)

• T cells that recognize naturally processed epitopes from prostein were expanded from healthy donors and characterized. T cells isolated from males were of low avidity and recognized subdominant epitopes while those from females were of higher avidity (PMID:15048720)
• Prostein is expressed in the vast majority of prostatic tissues, regardless of grade and metastatic status. No expression was detected in 4,700 normal and malignant tissue samples representing the great majority of essential tissues and tumors. (PMID:15176054)
• P501S is a sensitive and highly specific marker for identifying prostate tissue. Combined use of prostein/prostate specific antigen used to detect prostatic origin of metastatic carcinomas. (PMID:17721190)
• A SLC45A3:ETV5 gene fusion was identified in prostate cancer. (PMID:18172298)
• Intronic miRNAs from tissue-specific transcripts, or their natural absence, make cardinal contributions to cellular gene expression and phenotype. (PMID:18193184)
• SLC45A3-ELK4 may represent the first description of a recurrent RNA chimaeric transcript specific to prostate cancer that does not have a detectable DNA aberration (PMID:19136943)
• This study demonstrates that most ERG-overexpressing prostate cancers harbor hormonally regulated TMPRSS2-ERG, SLC45A3-ERG, or NDRG1-ERG fusions (PMID:19649210)
• This is the first study to report concurrent TMPRSS2 and SLC45A3 rearrangements in the same tumor focus in prostate cancer (PMID:20118910)
• Double sequential immunohistochemical staining with p63 and P501S is highly specific and can be a useful tool in distinguishing urothelial carcinoma from prostate carcinoma. (PMID:21777423)
• Data suggest that chimeric SLC45A3-ELK4 controls prostate cancer cell proliferation, and the chimera level correlates with prostate cancer disease progression. (PMID:22719019)
• This study provides first evidence that the expression of SLC45A3 protein is down regulated through SLC45A3-ERG fusion in prostate cancer. (PMID:22821757)
• Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population. (PMID:23269536)
• genome-wide association studies show that the top SNP associated with log PSA 9Prostate-specific antigen) levels was rs2153904 in SLC45A3. (PMID:25434496)
• CTCF has a role in regulating SLC45A3-ELK4 Chimeric RNA (PMID:26938874)
• Identification of a novel autoimmune peptide epitope of prostein in prostate cancer has been reported. (PMID:27700103)
• Novel loci for childhood body mass index and shared heritability with adult cardiometabolic traits. (PMID:33045005)
• Mapping genetic variability in mature miRNAs and miRNA binding sites in prostate cancer. (PMID:34099864)
• Prostein expression in human tumors: a tissue microarray study on 19,202 tumors from 152 different Tumor entities. (PMID:38218896)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc45a3	ENSDARG00000075975
mus_musculus	Slc45a3	ENSMUSG00000026435
rattus_norvegicus	Slc45a3	ENSRNOG00000007591
drosophila_melanogaster	Slc45-1	FBGN0035968
drosophila_melanogaster	lovit	FBGN0267429

Paralogs (3): SLC45A4 (ENSG00000022567), SLC45A1 (ENSG00000162426), SLC45A2 (ENSG00000164175)

Protein

Protein identifiers

Solute carrier family 45 member 3 — Q96JT2 (reviewed: Q96JT2)

Alternative names: Prostate cancer-associated protein 6, Prostein

All UniProt accessions (1): Q96JT2

UniProt curated annotations — full annotation on UniProt →

Function. Proton-associated sucrose transporter. May be able to transport also glucose and fructose.

Subcellular location. Membrane.

Tissue specificity. Prostate specific. Expressed in all prostatic glandular cells. Expressed both in normal and cancerous prostates.

Induction. Up-regulated by androgens.

Miscellaneous. Marker for prostate cells. May be used, in case of prostate cancers, as a target antigen for prostate carcinomas-directed cytotoxic T-cell lymphocytes.

Similarity. Belongs to the glycoside-pentoside-hexuronide (GPH) cation symporter transporter (TC 2.A.2) family.

RefSeq proteins (1): NP_149093* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011701	MFS	Family
IPR036259	MFS_trans_sf	Homologous_superfamily

Pfam: PF07690

Catalyzed reactions (Rhea), 1 shown:

• sucrose(out) + H(+)(out) = sucrose(in) + H(+)(in) (RHEA:72187)

UniProt features (12 total): transmembrane region 11, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96JT2-F1	77.39	0.43

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-189200	Cellular hexose transport
R-HSA-382551	Transport of small molecules
R-HSA-425407	SLC-mediated transmembrane transport

MSigDB gene sets: 145 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_CARBOHYDRATE_TRANSPORT, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_NEUROGENESIS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_KETONE_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_REGULATION_OF_FATTY_ACID_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_FATTY_ACID_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_LIPID_BIOSYNTHETIC_PROCESS, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_LIPID_METABOLIC_PROCESS

GO Biological Process (6): hexose transmembrane transport (GO:0008645), positive regulation of glucose metabolic process (GO:0010907), sucrose transport (GO:0015770), positive regulation of fatty acid biosynthetic process (GO:0045723), regulation of oligodendrocyte differentiation (GO:0048713), transmembrane transport (GO:0055085)

GO Molecular Function (4): sucrose:proton symporter activity (GO:0008506), sugar transmembrane transporter activity (GO:0051119), symporter activity (GO:0015293), transmembrane transporter activity (GO:0022857)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
SLC-mediated transmembrane transport	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
monosaccharide transmembrane transport	1
glucose metabolic process	1
regulation of glucose metabolic process	1
positive regulation of carbohydrate metabolic process	1
positive regulation of small molecule metabolic process	1
disaccharide transport	1
fatty acid biosynthetic process	1
regulation of fatty acid biosynthetic process	1
positive regulation of fatty acid metabolic process	1
positive regulation of lipid biosynthetic process	1
regulation of glial cell differentiation	1
oligodendrocyte differentiation	1
transport	1
cellular process	1
carbohydrate:proton symporter activity	1
sucrose:monoatomic cation symporter activity	1
carbohydrate transmembrane transporter activity	1
secondary active transmembrane transporter activity	1
transporter activity	1
transmembrane transport	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1058 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC45A3	ACP3	P15309	915
SLC45A3	KLK3	P07288	893
SLC45A3	ETV1	P50549	891
SLC45A3	KLKB1	P03952	859
SLC45A3	TMPRSS2	O15393	857
SLC45A3	KLK2	P20151	847
SLC45A3	ETV5	P41161	809
SLC45A3	PM20D1	Q6GTS8	808
SLC45A3	NUCKS1	Q9H1E3	803
SLC45A3	SLC41A1	Q8IVJ1	790
SLC45A3	ELK4	P28323	775
SLC45A3	MSMB	P08118	769
SLC45A3	ETV4	P43268	753
SLC45A3	RAB29	O14966	753
SLC45A3	AMACR	Q9UHK6	703

IntAct

3 interactions, top by confidence:

A	B	Type	Score
SLC45A3	FANCE	psi-mi:“MI:0915”(physical association)	0.400
SLC45A3	SHTN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (97): SLC45A3 (Affinity Capture-MS), FANCE (Affinity Capture-MS), SLC45A3 (Affinity Capture-RNA), APEX1 (Affinity Capture-MS), ATXN2 (Affinity Capture-MS), CALD1 (Affinity Capture-MS), CCDC124 (Affinity Capture-MS), CDC5L (Affinity Capture-MS), CDKN2AIP (Affinity Capture-MS), CNOT2 (Affinity Capture-MS), CSDE1 (Affinity Capture-MS), CSGALNACT2 (Affinity Capture-MS), CTTN (Affinity Capture-MS), DCTN2 (Affinity Capture-MS), DDX54 (Affinity Capture-MS)

ESM2 similar proteins: A0JP80, A1A5Z0, A5D6W6, A7YWN2, B2MVP8, B6CZ46, L5KLU7, O42153, O75783, O75908, O77759, O88908, P58872, P58873, P86243, Q1HG44, Q1KZG0, Q1XHX8, Q32LM8, Q49LS7, Q52KL1, Q5CZN0, Q5KR61, Q5T197, Q5TM67, Q5XIL6, Q6AX73, Q6AZ83, Q6MG14, Q6NSQ9, Q6P5W5, Q767L9, Q7TNJ2, Q7TQM4, Q80YU0, Q86VD9, Q8AVI9, Q8CIP5, Q8IWX5, Q8IXM6

Diamond homologs: A2ZN77, B8AF63, P58355, Q03411, Q0ILJ3, Q0P5V9, Q10R54, Q39231, Q39232, Q4LE88, Q5BKX6, Q6YK44, Q8BIV7, Q8K0H7, Q8K4S3, Q944W2, Q948L0, Q95KI5, Q96JT2, Q9FE59, Q9LKH3, Q9UMX9, Q9Y2W3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

74 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	66
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1216 predictions. Top by Δscore:

Variant	Effect	Δscore
1:205661858:TA:T	donor_loss	1.0000
1:205661860:CCT:C	donor_loss	1.0000
1:205661860:CCTG:C	donor_gain	1.0000
1:205662124:CGC:C	acceptor_gain	1.0000
1:205662827:CCTTA:C	donor_loss	1.0000
1:205662828:CTTAC:C	donor_loss	1.0000
1:205662829:TTA:T	donor_loss	1.0000
1:205662830:TA:T	donor_loss	1.0000
1:205662831:A:AT	donor_loss	1.0000
1:205661863:G:A	donor_gain	0.9900
1:205662125:GCC:G	acceptor_loss	0.9900
1:205662127:C:CC	acceptor_gain	0.9900
1:205663616:TGC:T	acceptor_gain	0.9900
1:205663619:C:CC	acceptor_gain	0.9900
1:205663619:CT:C	acceptor_loss	0.9900
1:205664483:AC:A	donor_gain	0.9900
1:205664484:CC:C	donor_gain	0.9900
1:205676679:C:T	acceptor_gain	0.9900
1:205680389:CCTA:C	donor_loss	0.9900
1:205680390:CTA:C	donor_loss	0.9900
1:205680393:C:CA	donor_loss	0.9900
1:205662065:C:CT	acceptor_gain	0.9800
1:205662125:GC:G	acceptor_gain	0.9800
1:205662126:CC:C	acceptor_gain	0.9800
1:205678660:A:AC	donor_gain	0.9800
1:205678661:C:CC	donor_gain	0.9800
1:205662123:ACGC:A	acceptor_gain	0.9700
1:205662124:CGCC:C	acceptor_gain	0.9700
1:205662831:A:AC	donor_gain	0.9700
1:205662832:C:CC	donor_gain	0.9700

AlphaMissense

3483 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:205662833:C:G	G320R	0.997
1:205662906:G:C	F295L	0.997
1:205662906:G:T	F295L	0.997
1:205662908:A:G	F295L	0.997
1:205662011:A:C	S358R	0.996
1:205662011:A:T	S358R	0.996
1:205662013:T:G	S358R	0.996
1:205662833:C:A	G320C	0.996
1:205662918:A:C	F291L	0.996
1:205662918:A:T	F291L	0.996
1:205662920:A:G	F291L	0.996
1:205661928:C:T	G386E	0.995
1:205662901:C:T	G297D	0.995
1:205662948:G:C	S281R	0.995
1:205662948:G:T	S281R	0.995
1:205662950:T:G	S281R	0.995
1:205663494:G:C	S99R	0.995
1:205663494:G:T	S99R	0.995
1:205663496:T:G	S99R	0.995
1:205661929:C:A	G386W	0.994
1:205662110:G:C	S325R	0.994
1:205662110:G:T	S325R	0.994
1:205662112:T:G	S325R	0.994
1:205663566:A:C	S75R	0.994
1:205663566:A:T	S75R	0.994
1:205663568:T:G	S75R	0.994
1:205661929:C:G	G386R	0.993
1:205661929:C:T	G386R	0.993
1:205662115:C:G	G324R	0.993
1:205663268:C:G	G175R	0.993

dbSNP variants (sampled 300 via entrez): RS1000303709 (1:205675187 G>C), RS1000346554 (1:205662919 A>T), RS1000465648 (1:205678564 C>T), RS1000557988 (1:205680470 C>T), RS1000575142 (1:205673702 G>A), RS1000672476 (1:205673986 G>A,C), RS1000979983 (1:205662351 G>A), RS1001118886 (1:205680093 G>A), RS1001159042 (1:205668520 C>A,G,T), RS1001202626 (1:205680359 C>T), RS1001457347 (1:205678452 G>C), RS1001460902 (1:205668344 C>T), RS1001619201 (1:205661521 A>T), RS1001787906 (1:205679655 G>A), RS1001794203 (1:205664588 C>G,T)

Disease associations

OMIM: gene MIM:605097 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): teratoma (MONDO:0002601)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

20 associations (top):

Study	Trait	p-value
GCST000530_4	Parkinson’s disease	2.000000e-12
GCST001134_2	White blood cell types	4.000000e-08
GCST001796_1	Prostate-specific antigen levels	2.000000e-19
GCST002476_1	Prostate-specific antigen levels	2.000000e-11
GCST002703_1	Prostate-specific antigen levels	1.000000e-13
GCST004093_26	Prostate-specific antigen levels	1.000000e-08
GCST004345_2	Elevated serum prostate-specific antigen levels in healthy men	3.000000e-20
GCST004618_2	White blood cell count (basophil)	5.000000e-12
GCST004631_46	Basophil percentage of white cells	9.000000e-12
GCST004634_5	Basophil percentage of granulocytes	2.000000e-10
GCST005976_12	White blood cell count (basophil)	3.000000e-15
GCST010697_7	Cortical surface area (min-P)	8.000000e-11
GCST010698_41	Subcortical volume (min-P)	8.000000e-12
GCST010699_29	Brain morphology (min-P)	3.000000e-09
GCST010700_18	Cortical thickness (MOSTest)	5.000000e-12
GCST010701_13	Cortical surface area (MOSTest)	3.000000e-08
GCST010702_124	Subcortical volume (MOSTest)	3.000000e-09
GCST010703_107	Brain morphology (MOSTest)	2.000000e-20
GCST90002394_94	Monocyte percentage of white cells	1.000000e-17
GCST90002409_15	Childhood body mass index	2.000000e-06

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0005090	basophil count
EFO:0007992	basophil percentage of leukocytes
EFO:0007995	basophil percentage of granulocytes
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness
EFO:0007989	monocyte percentage of leukocytes
EFO:0004340	body mass index

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D013724	Teratoma	C04.557.465.910

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067581 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC45 family of putative sugar transporters

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	increases reaction, affects expression, affects cotreatment, increases expression	4
Dihydrotestosterone	increases reaction, increases expression, decreases reaction	2
aristolochic acid I	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
sodium arsenite	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
merbarone	decreases reaction, increases expression	1
ICG 001	decreases expression	1
NSC 689534	affects binding, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Zoledronic Acid	decreases expression	1
Acetaminophen	decreases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Cadmium	decreases expression, increases response to substance	1
Copper	decreases expression, affects binding	1
Etoposide	decreases reaction, increases expression	1
Lead	affects expression	1
Lipopolysaccharides	increases expression, affects cotreatment, decreases expression, affects response to substance	1
Methyl Methanesulfonate	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	affects expression	1
Triclosan	increases expression	1
Metribolone	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5650462	Binding	Inhibition of human SLC45A3 at 10 uM by radioligand binding assay relative to control	Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. — Nature

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4PC	HCT116-SLC45A3-KO-c10	Cancer cell line	Male
CVCL_D4PD	HCT116-SLC45A3-KO-c6	Cancer cell line	Male
CVCL_TN79	HAP1 SLC45A3 (-) 1	Cancer cell line	Male
CVCL_TN80	HAP1 SLC45A3 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

18 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00104676	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
NCT02375204	PHASE3	ACTIVE_NOT_RECRUITING	Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
NCT00002931	PHASE2	COMPLETED	Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
NCT00301782	PHASE2	COMPLETED	Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors
NCT00432094	PHASE2	COMPLETED	Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
NCT00453232	PHASE2	COMPLETED	Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors
NCT00453310	PHASE2	COMPLETED	Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
NCT00470366	PHASE2	COMPLETED	Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
NCT02300987	PHASE2	COMPLETED	A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
NCT00003643	PHASE2/PHASE3	UNKNOWN	Combination Chemotherapy in Treating Men With Germ Cell Cancer
NCT00423852	PHASE1/PHASE2	COMPLETED	Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
NCT00687778	Not specified	UNKNOWN	11C-Acetate PET/CT Non-FDG-Avid Tumors
NCT00836121	Not specified	COMPLETED	Anterior Mediastinum Teratoma: A Case Report
NCT05179850	Not specified	UNKNOWN	Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children
NCT05187923	Not specified	UNKNOWN	Computer Aided Tool for Diagnosis of Neck Masses in Children
NCT05564026	Not specified	RECRUITING	Molecular Epidemiology of Pediatric Germ Cell Tumors
NCT06421805	Not specified	RECRUITING	Establishing Prospective Mediastinal Tumor Database of PUMCH
NCT07199699	Not specified	NOT_YET_RECRUITING	Subxiphoid VATS for Giant Mediastinal Teratoma